Bone Abstracts

Teriparatide is the active fragment (1–34) of the endogenous human parathyroid hormone (PTH). Studies showed that chronic administration of PTH results in decreased bone mass while intermittent exposure to PTH activates osteoblast bone deposition. Most of the structural studies published so far about the effect of Teriparatide focused their attention on the amount of newly-deposed bone without investigating the quality of the newly-formed bone tissue; moreover, most of th...